1. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine.
- Author
-
Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A, N'Diaye M, Sy MT, and Diouf F
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Diphtheria Toxoid administration & dosage, Diphtheria Toxoid immunology, Drug Combinations administration & dosage, Drug Combinations immunology, Drug Combinations standards, Epidemiologic Methods, Female, Humans, Immunization Schedule, Infant, Pertussis Vaccine administration & dosage, Pertussis Vaccine immunology, Pilot Projects, Poliomyelitis complications, Poliomyelitis epidemiology, Poliovirus Vaccine, Inactivated administration & dosage, Poliovirus Vaccine, Inactivated immunology, Rural Population, Seasons, Senegal, Tetanus Toxoid administration & dosage, Tetanus Toxoid immunology, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated immunology, Vaccines, Attenuated standards, Vaccines, Combined, Diphtheria Toxoid standards, Diphtheria-Tetanus-Pertussis Vaccine, Disease Outbreaks prevention & control, Pertussis Vaccine standards, Poliomyelitis prevention & control, Poliovirus Vaccine, Inactivated standards, Tetanus Toxoid standards
- Abstract
The 1986-87 outbreak of paralytic poliomyelitis in Senegal, with 676 reported cases, provided an opportunity to evaluate the efficacy of an enhanced-potency inactivated poliovirus vaccine (N-IPV) in the Kolda region, where this vaccine has been used since 1980. 89 cases, confirmed to have poliomyelitis with residual paralysis, were enrolled in a case-control study, up to 5 matched controls being obtained for each case. The clinical efficacy for one dose of N-IPV was 36% (95% confidence interval 0%, 67%) and for two doses was 89% (95% CI 62%, 97%).
- Published
- 1988
- Full Text
- View/download PDF